In Vitro Effect of Recombinant Human Adenovirus p53 Combined with Epirubicin on Human Gastric Cancer Cells
ZHANG Yanhua,XIE Yishan,LIU Shaoping,LIU Shiquan,Chunwei Peng,SHAO Lihua,LI Yan
DOI: https://doi.org/10.3969/j.issn.1000-8179.2010.18.002
2010-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: To study the effect of recombinant human adenovirus p53 injection (rAd-p53) and Epirubicin Hydrochloride (EPI) on human gastric cancer cells in vitro,and explore the therapeutic effect of gene therapy combined with chemotherapy on gastric cancer.Methods: The MGC-803 human gastric adenocarcinoma cell line was treated with rAd-p53 or/and EPI or left untreated as a blank control.Cell growth,flow cytometry,Wright's staining,and cyto-immunochemistry were used to analyze the therapeutic efficacy of the different treatment groups.Results: After treating MGC-803 on days 1,2,3 & 6,the cell inhibition rates were 34.52%,10.53%,58.98% and 79.17%,respectively,for rAd-p53 group; 60.71%,67.29%,73.21% and 95.14%,respectively,for EPI group; and 59.52%,66.17%,67.15% and 99.31%,respectively, for the combined group.The combined group was significantly higher than that of single agent groups (P<0.01).Based on the flow cytometry,we found that rAd-p53 blocked the cell cycle at G2/M phase (44.243%) and a higher Sub-G1 peak was observed.In the combined group,the G2/M phase (81.734%) and Sub-G1 peak were significantly evident (P<0.01). Decreased cell number,abnormal cell morphology and apoptotic cells were found under Wright's staining,and p53 protein stained positively in the nucleus and cytoplasm by immunochemical analysis in rAd-p53 treated group,especially in the combined treatment group.The EPI group was not different from the blank control.Conclusion: The gene therapy agent rAd-p53 has an inhibiting and apoptotic effect on MGC-803 cells,thus it could enhance the chemotherapeutic effect of EPI on MGC-803 cells,suggesting synergism between gene therapy and chemotherapy.